This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Infectious disease				
Sepsis	Leptin receptor (LEPR; CD295)	<p>Studies in mice suggest that leptin and its analogs could help treat sepsis. Systemic delivery of leptin to wild-type mice improved immune response and reduced organ damage during sepsis compared with no treatment. CNS delivery of leptin also increased survival during sepsis compared with vehicle. Next steps include testing the strategy in patients.</p> <p>Amylin Pharmaceuticals Inc. and Takeda Pharmaceutical Co. Ltd. are developing pramlintide/metreleptin, an amylin analog combined with a LEPR agonist that is in Phase II testing to treat obesity. Swedish Orphan Biovitrum has a LEPR agonist in preclinical testing for obesity.</p> <p>SciBX 3(18); doi:10.1038/scibx.2010.559 Published online May 6, 2010</p>	Findings unpatented; available for partnerships	<p>Tschöp, J. <i>et al. J. Neurosci.</i>; published online April 28, 2010; doi:10.1523/JNEUROSCI.4875-09.2010</p> <p>Contact: Matthias H. Tschöp, University of Cincinnati College of Medicine, Cincinnati, Ohio e-mail: matthias.tschop@uc.edu</p> <p>Contact: Charles C. Caldwell, same affiliation as above e-mail: charles.caldwell@uc.edu</p>